Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
Open Posted
- Opportunity number
- PAR-25-175
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Up to $500,000
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Categories
-
- Education
- Health
- Eligible applicants
-
- Higher Education Inst. (Public)
- Small Businesses
- Tribal Governments (Federally Recognized)
- Higher Education Inst. (Private)
- City/Township Governments
- 501(c)(3) Nonprofits
- Tribal Organizations (Not Federally Recognized)
- Public or Indian Housing Auth.
- Special District Governments
- For Profit Organizations
- Independent School Districts
- Other
- Non-501(c)(3) Nonprofits
- State Governments
- County Governments
- Points of contact
-
- NIH OER Webmaster grantsinfo@nih.gov
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Cancer Institute seeks R01 grant applications by January 7, 2028 for research projects integrating imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy to determine optimal use of those modalities in characterizing therapy response and/or emergence of resistance.
Eligible applicants include higher education institutions (public and private), small businesses, tribal governments (federally recognized and non-federally recognized), city and county governments, 501(c)(3) and non-501(c)(3) nonprofits, state governments, special district governments, independent school districts, public or Indian housing authorities, for-profit organizations, and other entities. The NOFO explicitly excludes non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations. Other eligible applicants specifically named include Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities, and Tribally Controlled Colleges and Universities.
The opportunity is assigned to two federal grant programs: Cancer Detection and Diagnosis Research (CFDA 93.394) and Cancer Treatment Research (CFDA 93.395). The source does not specify award ceilings, floors, expected number of awards, period of performance, place of performance, distinctive program objectives beyond the core focus, evaluation criteria weighting, or incumbent recipients.
Synopsis
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Files
| File | Type | Posted |
|---|---|---|
| PAR-25-175-Full-Announcement.html | HTML file | |
| PKG00288515.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity